Hepatitis B Control
Country Profile 2020
Hepatitis B Control

Country Profile 2020
Regional Progress
Hepatitis B vaccination coverage, 1990 – 2020

Source: WHO and UNICEF Joint Reporting Form on Immunization
Regional coverage is based on calculated average among all countries, whether they reported coverage or not
Regional Progress as of December 2020

Status of the 2020 Hepatitis B Control Milestone of <1% HBsAg Prevalence among 5 year old children

The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

© WHO Regional Office for the Western Pacific 2020. All rights reserved
### AMERICAN SAMOA

#### Demographics
- **Total population (2020):** 55,197
- **Births (2011):** 1,287
- **Surviving infants (2011):** 1,278
- **Urban population (2020):** 90%

#### Hepatitis B vaccine
- **HepB3 introduced nationwide:** 1986-1987
- **HepB birth dose introduced:** 1991
- **Current schedule:** 0, 1 month, 12 months
- **HepB3 type:** Monovalent

#### WHO verification
- **Status of verifying prevalence targets**
  - **Verification started:** February 2013
  - **Decision:** <1% in children
  - **Decision date:** October 2014

#### Neonatal deliveries

#### Hepatitis B vaccination coverage

#### 2020 Districts by coverage categories

### Vaccination coverage surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sample size</th>
<th>HepB BD %</th>
<th>HepB3 %</th>
<th>DTP3 %</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1990</td>
<td>National</td>
<td>3-4 years</td>
<td>95</td>
<td>not reported</td>
<td>82%</td>
<td>not reported</td>
<td>Mahoney Pac Hth Dialog 1996</td>
</tr>
<tr>
<td>1995</td>
<td>National</td>
<td>7-8 years</td>
<td>432</td>
<td>75%</td>
<td>91%</td>
<td>not reported</td>
<td>Bialek ISVHLD P351 2006</td>
</tr>
<tr>
<td>1996</td>
<td>National</td>
<td>7-8 years</td>
<td>435</td>
<td>not reported</td>
<td>87%</td>
<td>not reported</td>
<td>Mahoney Pac Hth Dialog 1996</td>
</tr>
<tr>
<td>2016</td>
<td>National</td>
<td>24-35 months</td>
<td>1180</td>
<td>97%</td>
<td>82%</td>
<td>85%</td>
<td>MMWR May 25, 2018 / 67(20);579-584</td>
</tr>
</tbody>
</table>

### Hepatitis B serological surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sampling base</th>
<th>Sample size</th>
<th>HBsAg prevalence (95%CI)</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1991</td>
<td>Tutuila</td>
<td>3-4 years</td>
<td>Community based</td>
<td>93</td>
<td>2.2%</td>
<td>Mahoney JID 2009</td>
</tr>
<tr>
<td>1995</td>
<td>National</td>
<td>7-8 years</td>
<td>Community based</td>
<td>432</td>
<td>0.5%</td>
<td>Bialek ISVHLD P351 2006</td>
</tr>
<tr>
<td>2011</td>
<td>National</td>
<td>6 years</td>
<td>School based</td>
<td>562</td>
<td>0.2%</td>
<td>Govt American Samoa 2012</td>
</tr>
</tbody>
</table>

**Abbreviations:** DTP3: 3rd dose of Diphtheria, Tetanus and Pertussis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours

**Sources:** Total population was from the United Nations World Population Prospects the 2020 revision; Urban Population was derived from World Bank; Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization
**Demographics**

- Total population (2020): 25,499,881
- Births (2020): 318,478
- Surviving infants (2020): 317,554
- Urban population (2020): 86%

**Hepatitis B vaccine**

- HepB3 introduced nationwide: 2000
- HepB birth dose introduced: 2000
- Current schedule: 0, 2 months, 4 months, 6 months
- HepB3 type: DTP-Hib-HepB-IPV

**WHO verification**

- Status of verifying prevalence targets
  - Verification started: June 2012
  - Decision: <1% in children
  - Decision date: December 2012

**Neonatal deliveries**

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sample size</th>
<th>HepB BD %</th>
<th>HepB3 %</th>
<th>DTP3 %</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2007</td>
<td>National</td>
<td>12 months</td>
<td>280,874</td>
<td>not reported</td>
<td>94%</td>
<td>92%</td>
<td>From National Health Insurance covering 99% of population</td>
</tr>
</tbody>
</table>

**Hepatitis B vaccination coverage**

- Districts by coverage categories

**Hepatitis B serological surveys**

- Survey year: 2002
- Location: National
- Ages enrolled: 1-9 years
- Sampling base: Hospital based
- Sample size: 249
- HBsAg prevalence (95%CI): 0.4% (0.0% - 2.2%)
- Reference/Notes: Gidding Vaccine 2007

**Abbreviations:** DTP3: 3rd dose of Diphteria, Tetanus and Pertusis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours

**Sources:** Total population, births and surviving infants were from the United Nations World Population Prospects the 2020 revision; Urban Population was derived from World Bank; Neonatal deliveries was derived from UNICEF’s Maternal and Newborn Health Coverage Database for delivery in health facility and World Bank’s World Development Indicators for SBA (most recent data); Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization

*HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage.*
BRUNEI DARUSSALAM

Demographics

- Total population (2020): 437,483
- Births (2020): 6,156
- Surviving infants (2020): 6,110
- Urban population (2020): 80%

Hepatitis B vaccine

- HepB3 introduced nationwide: 1988
- HepB birth dose introduced: 1988
- Current schedule: 0, 2 months, 4 months, 6 months
- HepB3 type: DTP-Hib-HepB-IPV

Neonatal deliveries

- Women aged 15-49
- Women aged 15-19
- In health facility
- Skilled birth attendant

Hepatitis B vaccination coverage

2020 Districts by coverage categories*

- <50%
- 50%-79%
- 80%-89%
- 90%-94%
- >94%

WHO verification

- Status of verifying prevalence targets
  - Verification started: March 2013
  - Decision: <1% in children
  - Decision date: June 2013

status of verifying prevalence targets

Vaccination coverage surveys

Survey year | Location | Ages enrolled | Sample size | HepB BD % | HepB3 % | DTP3 % | Reference/Notes
---|---|---|---|---|---|---|---
2011 National 8-9 years School based 4,513 0.09% MoH Brunei 2012

Hepatitis B serological surveys

Survey year | Location | Ages enrolled | Sampling base | Sample size | HBsAg prevalence (95%CI) | Reference/Notes
---|---|---|---|---|---|---
2011 National 8-9 years School based 4,513

Abbreviations: DTP3: 3rd dose of Diphteria, Tetanus and Pertusis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours
Sources: Total population, births and surviving infants were from the United Nations World Population Prospects the 2020 revision; Urban Population was derived from World Bank; Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization
*HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage.
CAMBODIA

Demographics

- Total population (2020): 16,718,971
- Births (2020): 360,189
- Surviving infants (2020): 352,521
- Urban population (2020): 24%

Hepatitis B vaccine

- HepB3 introduced nationwide: 2005
- HepB birth dose introduced: 2005
- Current schedule: 0, 6 weeks, 10 weeks, 14 weeks
- HepB3 type: DTP-Hib-HepB

WHO verification

- Status of verifying prevalence targets
- Verification started: January 2018
- Decision: <1% in children
- Decision date: June 2018

Neonatal deliveries

- Total population (2020): 16,718,971
- Births (2020): 360,189
- Surviving infants (2020): 352,521
- Urban population (2020): 24%

Vaccination coverage surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sample size</th>
<th>HepB BD %</th>
<th>HepB3 %</th>
<th>DTP3 %</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2005</td>
<td>National</td>
<td>12-23 months</td>
<td>1517</td>
<td>not reported</td>
<td>not reported</td>
<td>78%</td>
<td>DHS Survey</td>
</tr>
<tr>
<td>2009</td>
<td>National</td>
<td>12-23 months</td>
<td>1068</td>
<td>61%</td>
<td>not reported</td>
<td>56%</td>
<td>Cambodia Socio-Economic Survey 2009 (confirmation method only by card)</td>
</tr>
<tr>
<td>2010</td>
<td>National</td>
<td>12-23 months</td>
<td>1614</td>
<td>73%</td>
<td>84%</td>
<td>84%</td>
<td>DHS Survey: HepB BD 73%, HepB3 85%, DTP3 85% by 12 months</td>
</tr>
<tr>
<td>2014</td>
<td>National</td>
<td>12-23 months</td>
<td>1460</td>
<td>83%</td>
<td>84%</td>
<td>84%</td>
<td>DHS Survey: HepB BD 83%, HepB3 82%, DTP3 82% by 12 months</td>
</tr>
</tbody>
</table>

Hepatitis B serological surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sampling base</th>
<th>Sample size</th>
<th>HBSAg prevalence (95%CI)</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2001</td>
<td>Kg Chhnang</td>
<td>9-17 months</td>
<td>Hospital based</td>
<td>900</td>
<td>2.7%</td>
<td>Report MoH/PATH/AIHI</td>
</tr>
<tr>
<td>2006</td>
<td>National</td>
<td>5 years</td>
<td>Community based</td>
<td>1,558</td>
<td>3.5% (2.4% - 4.8%)</td>
<td>Soeung AMTH 2009</td>
</tr>
<tr>
<td>2011</td>
<td>Urban, Rural, Remote</td>
<td>4-5 years</td>
<td>Community based</td>
<td>2,429</td>
<td>0.3%, 1.4%, 3.5%</td>
<td>Mao Vaccine 2013</td>
</tr>
<tr>
<td>2017</td>
<td>National</td>
<td>5-6 years</td>
<td>Community based</td>
<td>2,520</td>
<td>0.6% (0.3% - 1.0%)</td>
<td>Cambodia MOH 2017 preliminary data</td>
</tr>
<tr>
<td>2017</td>
<td>National</td>
<td>5-7 years</td>
<td>Cross-sectional survey</td>
<td>2,520</td>
<td>0.56%</td>
<td>Ork Vaccine 2019</td>
</tr>
</tbody>
</table>

Abbreviations:
- DTP3: 3rd dose of Diphtheria, Tetanus and Pertussis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBSAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours
- Sources: Total population, births and surviving infants were from the United Nations World Population Prospects the 2020 revision; Urban Population was derived from World Bank; Neonatal deliveries was derived from UNICEF Maternal and Newborn Health Coverage Database (most recent data); Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization

*HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage.
**CHINA**

### Demographics
- Total population (2020): 1,439,323,774
- Births (2020): 16,233,446
- Surviving infants (2020): 16,086,657
- Urban population (2020): 61%

### Hepatitis B vaccine
- HepB3 introduced nationwide: 1992
- HepB birth dose introduced: 1992
- Current schedule: 0, 1 month, 6 months
- HepB3 type: Monovalent

### WHO verification
- Status of verifying prevalence targets
  - Verification started: February 2012
  - Decision: <1% in children
  - Decision date: June 2012

### Vaccination coverage surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sample size</th>
<th>HepB BD %</th>
<th>HepB3 %</th>
<th>DTP3 %</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2004</td>
<td>National</td>
<td>12-23 months</td>
<td>1,188</td>
<td>not reported</td>
<td>85%</td>
<td>not reported</td>
<td>The National EPI Evaluation Report 2004 (Confirmation method by card only); 90% HepB3 by 12 months</td>
</tr>
<tr>
<td>2006</td>
<td>National</td>
<td>1 year</td>
<td>3,636</td>
<td>93%</td>
<td>83%</td>
<td>not reported</td>
<td>Liang JID 2009; 2005 birth cohort</td>
</tr>
<tr>
<td>2008</td>
<td>National</td>
<td>12-23 months</td>
<td>9,762</td>
<td>not reported</td>
<td>93%</td>
<td>91%</td>
<td>Analysis Report of National Health Services Survey in China</td>
</tr>
</tbody>
</table>

### Hepatitis B serological surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sampling base</th>
<th>Sample size</th>
<th>HBsAg prevalence (95%CI)</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2006</td>
<td>National</td>
<td>1-4 years</td>
<td>Community based</td>
<td>16,376</td>
<td>1.0% (0.8% - 1.2%)</td>
<td>Liang JID 2009</td>
</tr>
<tr>
<td>2006</td>
<td>National</td>
<td>5 years</td>
<td>Community based</td>
<td>2,215</td>
<td>1.1% (0.4% - 1.8%)</td>
<td>Liang JID 2009</td>
</tr>
<tr>
<td>2006</td>
<td>National</td>
<td>6 years</td>
<td>Community based</td>
<td>2,236</td>
<td>0.9% (0.4% - 1.5%)</td>
<td>Liang JID 2009</td>
</tr>
<tr>
<td>2012</td>
<td>National</td>
<td>1-4 years</td>
<td>Community based</td>
<td>5,474</td>
<td>0.5% (0.3% - 0.7%)</td>
<td>Yonghao International Journal of Infectious Diseases 2015</td>
</tr>
<tr>
<td>2012</td>
<td>National</td>
<td>5-9 years</td>
<td>Community based</td>
<td>4,407</td>
<td>0.7% (0.5% - 1.0%)</td>
<td>Yonghao International Journal of Infectious Diseases 2015</td>
</tr>
<tr>
<td>2012</td>
<td>National</td>
<td>10-14 years</td>
<td>Community based</td>
<td>3,326</td>
<td>1.2% (0.8% - 1.6%)</td>
<td>Yonghao International Journal of Infectious Diseases 2015</td>
</tr>
<tr>
<td>2014</td>
<td>National</td>
<td>1-4 years</td>
<td>Community based</td>
<td>12,681</td>
<td>0.3% (0.2% - 0.5%)</td>
<td>Cui QF Emerging Infectious Diseases 2017</td>
</tr>
<tr>
<td>2014</td>
<td>National</td>
<td>5-14 years</td>
<td>Community based</td>
<td>9,738</td>
<td>0.9% (0.7% - 1.3%)</td>
<td>Cui QF Emerging Infectious Diseases 2017</td>
</tr>
<tr>
<td>2014</td>
<td>National</td>
<td>15-29 years</td>
<td>Community based</td>
<td>9,294</td>
<td>4.4% (3.8% - 5.1%)</td>
<td>Cui QF Emerging Infectious Diseases 2017</td>
</tr>
</tbody>
</table>

**Abbreviations:** DTP3: 3rd dose of Diphtheria, Tetanus and Pertussis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours

**Sources:** Total population, births and surviving infants were from the United Nations World Population Prospects the 2020 revision; Urban Population was derived from World Bank; Neonatal deliveries was derived from UNICEF Maternal and Newborn Health Coverage Database (most recent data); Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization

*HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage.*
Demographics

- Total population (2020): 7,496,988
- Births (2020): 82,839
- Surviving infants (2020): 82,736
- Urban population (2020): 100%

Hepatitis B vaccine

- HepB3 introduced nationwide: 1988
- HepB birth dose introduced: 1988
- Current schedule: 0, 1 month, 6 months
- HepB3 type: Monovalent

WHO verification

- Status of verifying prevalence targets
  - Verification started: February 2011
  - Decision: <1% in children
  - Decision date: July 2011

Neonatal deliveries

- Total population (2020): 7,496,988
- Births (2020): 82,839
- Surviving infants (2020): 82,736
- Urban population (2020): 100%

Hepatitis B vaccination coverage

- Timely HepB BD
- Any HepB BD
- HepB3

2020 Districts by coverage categories

Vaccination coverage surveys

- Survey year
- Location
- Ages enrolled
- Sample size
- HepB BD %
- HepB3 %
- DTP3 %
- Reference/Notes

<table>
<thead>
<tr>
<th>Year</th>
<th>Location</th>
<th>Ages Enrolled</th>
<th>Sample Size</th>
<th>HepB BD %</th>
<th>HepB3 %</th>
<th>DTP3 %</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2009</td>
<td>National</td>
<td>2-5 years</td>
<td>6248</td>
<td>not reported</td>
<td>≥99.5%</td>
<td>&gt;99.8%</td>
<td>MoH Hong Kong 2011</td>
</tr>
<tr>
<td>2015</td>
<td>National</td>
<td>2-5 years</td>
<td>not reported</td>
<td>&gt;95.0%</td>
<td>&gt;95.0%</td>
<td>&gt;95.0%</td>
<td>WHO-UNICEF Joint Reporting Form (data for 2017)</td>
</tr>
</tbody>
</table>

Hepatitis B serological surveys

- Survey year
- Location
- Ages enrolled
- Sampling base
- Sample size
- HBsAg prevalence (95%CI)
- Reference/Notes

<table>
<thead>
<tr>
<th>Year</th>
<th>Location</th>
<th>Ages Enrolled</th>
<th>Sampling Base</th>
<th>Sample Size</th>
<th>HBsAg Prevalence (95%CI)</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2006</td>
<td>National</td>
<td>1-4 years</td>
<td>Laboratory</td>
<td>196</td>
<td>1%</td>
<td>MoH Hong Kong 2011</td>
</tr>
<tr>
<td>2009</td>
<td>National</td>
<td>12-15 years</td>
<td>School</td>
<td>1913</td>
<td>0.8% (0.4% - 1.2%)</td>
<td>MoH Hong Kong 2011</td>
</tr>
</tbody>
</table>

Abbreviations: DTP3: 3rd dose of Diptheria, Tetanus and Pertussis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours

Sources: Total population, births and surviving infants were from the United Nations World Population Prospects the 2020 revision; Urban Population was derived from World Bank; Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization.
MACAO SAR (CHINA)

Demographics
- Total population (2020): 649,342
- Births (2020): 6,961
- Surviving infants (2019): 6,944
- Urban population (2020): 100%

Hepatitis B vaccine
- HepB3 introduced nationwide: 1984
- HepB birth dose introduced: 1989
- Current schedule: 0, 1 month, 6 months
- HepB3 type: Monovalent

Vaccination coverage surveys
<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sample size</th>
<th>HepB BD %</th>
<th>HepB3 %</th>
<th>DTP3 %</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2003</td>
<td>National</td>
<td>6-9 years</td>
<td>School based</td>
<td>437</td>
<td>0%</td>
<td></td>
<td>MoH Macao 2008</td>
</tr>
</tbody>
</table>

Hepatitis B serological surveys
<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sampling base</th>
<th>Sample size</th>
<th>HBsAg prevalence (95%CI)</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2003</td>
<td>National</td>
<td>6-9 years</td>
<td>School based</td>
<td>437</td>
<td>0% (0% - 0.7%)</td>
<td>MoH Macao 2008</td>
</tr>
</tbody>
</table>

WHO verification
- Status of verifying prevalence targets
  - Verification started: April 2008
  - Decision: <1% in children
  - Decision date: August 2008

Abbreviations: DTP3: 3rd dose of Diphteria, Tetanus and Pertusis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours

Sources: Total population, births and surviving infants were from the United Nations World Population Prospects the 2020 revision; Urban Population was derived from World Bank; Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization
### Demographics

- **Total population (2020)**: 17,564
- **Births (2019)**: 218
- **Surviving infants (2019)**: 218
- **Urban population (2020)**: 75%

### Hepatitis B vaccine

- **HepB3 introduced nationwide**: 1989
- **HepB birth dose introduced**: 1989
- **Current schedule**: 0, 6 weeks, 3 months, 5 months
- **HepB3 type**: DTP-Hib-HepB

### WHO verification

- **Status of verifying prevalence targets**
  - Verification started: January 2013
  - Decision: <1% in children
  - Decision date: October 2013

### Neonatal deliveries

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sample size</th>
<th>HepB BD %</th>
<th>HepB3 %</th>
<th>DTP3 %</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2012</td>
<td>7 of 11 islands</td>
<td>6 years</td>
<td>269</td>
<td></td>
<td></td>
<td></td>
<td>Patel Vaccine 2016</td>
</tr>
</tbody>
</table>

### Vaccination coverage surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sample size</th>
<th>HepB BD %</th>
<th>HepB3 %</th>
<th>DTP3 %</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2012</td>
<td>7 of 11 islands</td>
<td>6 years</td>
<td>269</td>
<td></td>
<td></td>
<td></td>
<td>Patel Vaccine 2016</td>
</tr>
</tbody>
</table>

### Hepatitis B serological surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sampling base</th>
<th>Sample size</th>
<th>HBsAg prevalence (95%CI)</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2012</td>
<td>7 of 11 islands</td>
<td>6 years</td>
<td>School based</td>
<td>269</td>
<td>0%</td>
<td>Patel Vaccine 2016</td>
</tr>
</tbody>
</table>

**Abbreviations**: DTP3: 3rd dose of Diphteria, Tetanus and Pertusis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours

**Sources**: Total population was from the United Nations World Population Prospects the 2020 revision; Urban Population was derived from World Bank; Neonatal deliveries was derived from UNICEF Maternal and Newborn Health Coverage Database (most recent data); Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization.
FIJI

Demographics
- Total population (2020): 896,444
- Births (2020): 18,472
- Surviving infants (2020): 18,112
- Urban population (2020): 59%

Hepatitis B vaccine
- HepB3 introduced nationwide: 1989
- HepB birth dose introduced: 1989
- Current schedule: 0, 6 weeks, 10 weeks, 14 weeks
- HepB3 type: DTP-Hib-HepB

Vaccination coverage surveys
<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sample size</th>
<th>HepB BD %</th>
<th>HepB3 %</th>
<th>DTP3 %</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1999</td>
<td>National</td>
<td>12-23 months</td>
<td>not reported</td>
<td>not reported</td>
<td>94%</td>
<td>92%</td>
<td>Fiji National EPI Survey</td>
</tr>
<tr>
<td>2005</td>
<td>National</td>
<td>12-23 months</td>
<td>630</td>
<td>not reported</td>
<td>92%</td>
<td>83%</td>
<td>Fiji Immunization Coverage Survey Report</td>
</tr>
<tr>
<td>2008</td>
<td>National</td>
<td>15-26 months</td>
<td>1200</td>
<td>86%</td>
<td>99%</td>
<td>99%</td>
<td>Fiji National Immunisation Coverage Survey</td>
</tr>
<tr>
<td>2013</td>
<td>National</td>
<td>not reported</td>
<td>not reported</td>
<td>not reported</td>
<td>not reported</td>
<td>91%</td>
<td>WHO-UNICEF Joint Reporting Form (Data for 2014)</td>
</tr>
</tbody>
</table>

Hepatitis B serological surveys
<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sampling base</th>
<th>Sample size</th>
<th>HBsAg prevalence (95%CI)</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1998</td>
<td>Large Towns</td>
<td>12-24 months</td>
<td>Hospital based</td>
<td>285</td>
<td>0.7%</td>
<td>Wilson Vaccine 2000</td>
</tr>
<tr>
<td>2008</td>
<td>Sub-national</td>
<td>6 months-5 years</td>
<td>Community based</td>
<td>428</td>
<td>0%</td>
<td>WHO:RS/2009/GE/23(JPN)</td>
</tr>
</tbody>
</table>

WHO verification
- Status of verifying prevalence targets
  - Verification started: pending
  - Decision: n.a.
  - Decision date: n.a.

Neonatal deliveries
- Women aged 15-49: 100%
- Women aged 15-19: 90%
- In health facility: 80%

Vaccination coverage
- 2016-2020: Timely HepB BD, Any HepB BD, and HepB3

2020 Districts by coverage categories

Abbreviations: DTP3: 3rd dose of Diphtheria, Tetanus and Pertussis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours
Sources: Total population, births and surviving infants were from the United Nations World Population Prospects the 2020 revision; Urban Population was derived from World Bank; Neonatal deliveries was derived from UNICEF Maternal and Newborn Health Coverage Database (most recent data); Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization
HepB3 coverage at national and district level are inconsistent due to different data sources used by Fiji.

*HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage.
### Demographics
- Total population (2020): 280,904
- Births (2020): 3,983
- Surviving infants (2020): 3,958
- Urban population (2020): 64%

### Hepatitis B vaccine
- HepB3 introduced nationwide: 1992
- HepB birth dose introduced: 1992
- Current schedule: 0, 2 months, 10 months
- HepB3 type: DTP-Hib-HepB-IPV

#### WHO verification
- Status of verifying prevalence targets:
  - Verification started: February 2016
  - Decision: <1% in children
  - Decision date: September 2016

### Neonatal deliveries

### Hepatitis B vaccination coverage

### 2020 Districts by coverage categories

### Vaccination coverage surveys

### Hepatitis B serological surveys

#### Abbreviations:
- DTP3: 3rd dose of Diphtheria, Tetanus and Pertussis vaccine
- HepB3: at least 3 doses of hepatitis B vaccine
- HBsAg: hepatitis B surface antigen
- SBA: Skilled Birth Attendant
- Timely HepB BD: birth dose within 24 hours

#### Sources:
- Total population, births and surviving infants were from the United Nations World Population Prospects the 2020 revision
- Urban Population was derived from World Bank
- Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization
GUAM

Demographics

<table>
<thead>
<tr>
<th>Total population (2020)</th>
<th>168 783</th>
</tr>
</thead>
<tbody>
<tr>
<td>Births (2020)</td>
<td>2 756</td>
</tr>
<tr>
<td>Surviving infants (2020)</td>
<td>2 734</td>
</tr>
<tr>
<td>Urban population (2020)</td>
<td>95%</td>
</tr>
</tbody>
</table>

Hepatitis B vaccine

- HepB3 introduced nationwide: 1988
- HepB birth dose introduced: 1988
- Current schedule: 0, 1-2 months, 6 months
- HepB3 type: Monovalent

WHO verification

- Status of verifying prevalence targets
  - Verification started: October 2015
  - Decision: <1% in children
  - Decision date: June 2016

Neonatal deliveries

- Total population (2020): 168 783
- Births (2020): 2 756
- Surviving infants (2020): 2 734
- Urban population (2020): 95%
- HepB3 introduced nationwide: 1988
- HepB birth dose introduced: 1988
- Current schedule: 0, 1-2 months, 6 months
- HepB3 type: Monovalent

Hepatitis B vaccination coverage

- Survey year
- Location
- Ages enrolled
- Sample size
- HepB BD %
- HepB3 %
- DTP3 %
- Reference/Notes

2020 Districts by coverage categories

Survey year

- 2015

Survey Location Ages enrolled Sampling base Sample size HBsAg prevalence (95%CI) Reference/Notes

2015 National 6 years School based 1484 0.0% Guam DoH & Social Services 2015

Abbreviations:
- DTP3: 3rd dose of Diptheria, Tetanus and Pertussis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours

Sources:
- Total population, births and surviving infants were from the United Nations World Population Prospects the 2020 revision; Urban Population was derived from World Bank; Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization.
Demographics

- Total population (2020): 126,476,458
- Births (2020): 908,919
- Surviving infants (2020): 907,427
- Urban population (2020): 92%

Hepatitis B vaccine

- HepB3 introduced nationwide: October 2016
- HepB birth dose introduced: If born to HBsAg+ mothers
- Current schedule: 2 months, 3 months, 7 months
- HepB3 type: Monovalent

WHO verification

- Status of verifying prevalence targets
  - Verification started: pending
  - Decision: n.a.
  - Decision date: n.a.

Neonatal deliveries

Vaccination coverage surveys

- Survey year
- Location
- Ages enrolled
- Sample size
- HepB BD %
- HepB3 %
- DTP3 %
- Reference/Notes

Hepatitis B serological surveys

- Survey year
- Location
- Ages enrolled
- Sampling base
- Sample size
- HBsAg prevalence (95%CI)
- Reference/Notes

Abbreviations:
- DTP3: 3rd dose of Diphtheria, Tetanus and Pertussis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours
- Sources: Total population, births and surviving infants were from the United Nations World Population Prospects the 2020 revision; Urban Population was derived from World Bank; Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization
KIRIBATI

**Demographics**

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Total population (2020)</td>
<td>119,446</td>
</tr>
<tr>
<td>Births (2020)</td>
<td>3,233</td>
</tr>
<tr>
<td>Surviving infants (2020)</td>
<td>3,104</td>
</tr>
<tr>
<td>Urban population (2020)</td>
<td>57%</td>
</tr>
</tbody>
</table>

**Hepatitis B vaccine**

- HepB3 introduced nationwide: 1995
- HepB birth dose introduced: 1990
- Current schedule: 0, 6 weeks, 10 weeks, 14 weeks
- HepB3 type: DTP-Hib-HepB

**WHO verification**

- Status of verifying prevalence targets
  - Verification started: pending
  - Decision: n.a.
  - Decision date: n.a.

**Neonatal deliveries**

**Hepatitis B vaccination coverage**

**Survey year** | **Location** | **Ages enrolled** | **Sample size** | **HepB BD %** | **HepB3 %** | **DTP3 %** | **Reference/Notes** |
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>2009</td>
<td>National</td>
<td>48-59 months</td>
<td>181</td>
<td>not reported</td>
<td>not reported</td>
<td>32%</td>
<td>DHS Survey; by 12 months</td>
</tr>
<tr>
<td>2009</td>
<td>National</td>
<td>36-47 months</td>
<td>200</td>
<td>not reported</td>
<td>not reported</td>
<td>42%</td>
<td>DHS Survey; by 12 months</td>
</tr>
<tr>
<td>2009</td>
<td>National</td>
<td>24-35 months</td>
<td>202</td>
<td>not reported</td>
<td>not reported</td>
<td>50%</td>
<td>DHS Survey; by 12 months</td>
</tr>
<tr>
<td>2009</td>
<td>National</td>
<td>12-23 months</td>
<td>233</td>
<td>not reported</td>
<td>61%</td>
<td>61%</td>
<td>DHS Survey: HepB3 58%, DTP3 58% by 12 months</td>
</tr>
</tbody>
</table>

**Vaccination coverage surveys**

**Survey year** | **Location** | **Ages enrolled** | **Sample size** | **HBsAg prevalence (95% CI)** | **Reference/Notes** |
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>1998</td>
<td>Large Towns</td>
<td>12-24 months</td>
<td>Hospital based</td>
<td>156</td>
<td>3.8%</td>
</tr>
<tr>
<td>2014</td>
<td>National</td>
<td>5-9 years</td>
<td>Community based</td>
<td>1249</td>
<td>3.3% (2.4% - 4.6%)</td>
</tr>
</tbody>
</table>

**Hepatitis B serological surveys**

**Survey year** | **Location** | **Ages enrolled** | **Sampling base** | **Sample size** | **HBsAg prevalence (95% CI)** | **Reference/Notes** |
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>1998</td>
<td>Large Towns</td>
<td>12-24 months</td>
<td>Hospital based</td>
<td>156</td>
<td>3.8%</td>
<td>Wilson Vaccine 2000</td>
</tr>
<tr>
<td>2014</td>
<td>National</td>
<td>5-9 years</td>
<td>Community based</td>
<td>1249</td>
<td>3.3% (2.4% - 4.6%)</td>
<td>Patel Vaccine 2016</td>
</tr>
</tbody>
</table>

**Abbreviations:**
- DTP3: 3rd dose of Diphtheria, Tetanus and Pertussis vaccine
- HepB3: at least 3 doses of hepatitis B vaccine
- HBsAg: hepatitis B surface antigen
- SBA: Skilled Birth Attendant
- Timely HepB BD: birth dose within 24 hours

**Sources:**
- Total population, births and surviving infants were from the United Nations World Population Prospects the 2020 revision
- Urban Population was derived from World Bank
- Neonatal deliveries was derived from UNICEF Maternal and Newborn Health Coverage Database (most recent data)
- Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization

*HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage.*
LAO PEOPLE’S DEMOCRATIC REPUBLIC

Demographics
- Total population (2020): 7,275,556
- Births (2020): 164,753
- Surviving infants (2020): 158,882
- Urban population (2020): 36%

Hepatitis B vaccine
- HepB3 introduced nationwide: 2001
- HepB birth dose introduced: 2004
- Current schedule: 0, 6 weeks, 10 weeks, 14 weeks
- HepB3 type: DTP-Hib-HepB

WHO verification
- Status of verifying prevalence targets: pending
- Verification started: n.a.
- Decision: n.a.
- Decision date: n.a.

Neonatal deliveries
- Women aged 15-49: 29%
- Women aged 15-19: 29%
- In health facility: 42%

Hepatitis B vaccination coverage
- 2016: 37%, 55%
- 2017: 46%, 61%
- 2018: 54%, 67%
- 2019: 62%, 74%
- 2020: 70%, 86%

Vaccination coverage surveys
- Survey year: 2006
  - Location: National
  - Ages enrolled: 12-23 months
  - Sample size: 828
  - HepB BD %: not reported
  - HepB3 %: not reported
  - DTP3 %: 41%
  - Reference/Notes: Lao PDR Multiple Indicator Cluster Survey 2006 Final Report; DTP3 32% by 12 months
- Survey year: 2015
  - Location: National
  - Ages enrolled: 12-23 months
  - Sample size: 5981
  - HepB3 %: 72%
  - HepB3 %: 81%
  - DTP3 %: 81%
  - Reference/Notes: National Immunization Survey

Hepatitis B serological surveys
- Survey year: 2012
  - Location: National
  - Ages enrolled: 5-9 years
  - Sampling base: Community based
  - Sample size: 965
  - HBsAg prevalence (95%CI): 1.7% (0.8% - 2.6%)
  - Reference/Notes: Xeuatvongsa PloS ONE 2014

Abbreviations: DTP3: 3rd dose of Diphteria, Tetanus and Pertusis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours
Sources: Total population, births and surviving infants were from the United Nations World Population Prospects the 2020 revision; Urban Population was derived from World Bank; Neonatal deliveries was derived from UNICEF Maternal and Newborn Health Coverage Database (most recent data); Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization
**HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage.**
MALAYSIA

Demographics
Total population (2020) 32 365 998
Births (2020) 531 804
Surviving infants (2020) 528 868
Urban population (2020) 78%

Hepatitis B vaccine
HepB3 introduced nationwide 1989
HepB birth dose introduced 1989
Current schedule 0, 1 month, 6 months
HepB3 type Monovalent

Vaccination coverage surveys
Survey year Location Ages enrolled Sample size HepB BD % HepB3 % DTP3 % Reference/Notes
1997-2007 National 6-9 years School based 193 717 0.40% MoH Malaysia 2011
2003 National 7 years School based 12 269 0.40% Ng Med Microb Imm 2005
2007 National 7-9 years Community based 1735 0.30% MoH Malaysia 2008
2009 National 9 years School based 2938 0.2% (0% - 0.3%) MoH Malaysia 2011
2009 National 10 years School based 3265 0.4% (0.2% - 0.6%) MoH Malaysia 2011

WHO verification
Status of verifying prevalence targets
Verification started: March 2011
Decision: <1% in children
Decision date: July 2011

Abbreviations: DTP3: 3rd dose of Diphteria, Tetanus and Pertusis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours
Sources: Total population, births and surviving infants were from the United Nations World Population Prospects the 2020 revision; Urban Population was derived from World Bank; Neonatal deliveries was derived from UNICEF Maternal and Newborn Health Coverage Database (most recent data); Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization

*HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage.
## Demographics

<table>
<thead>
<tr>
<th>Total population (2020)</th>
<th>59,194</th>
</tr>
</thead>
<tbody>
<tr>
<td>Births (2019)</td>
<td>1,090</td>
</tr>
<tr>
<td>Surviving infants (2019)</td>
<td>1,068</td>
</tr>
<tr>
<td>Urban population (2020)</td>
<td>70%</td>
</tr>
</tbody>
</table>

## Hepatitis B vaccine

### Hepatitis B serological surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sampling base</th>
<th>Sample size</th>
<th>HBsAg prevalence (95%CI)</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2007</td>
<td>Majuro, Ebeye</td>
<td>5-9 years</td>
<td>School based</td>
<td>331</td>
<td>1.8% (0.4% - 3.3%)</td>
<td>Bialek PID 2010</td>
</tr>
<tr>
<td>2016</td>
<td>National</td>
<td>5-6 years</td>
<td>School based</td>
<td>1148</td>
<td>1.2% (0.6% - 1.9%)</td>
<td>2018 MoH Marshall Islands</td>
</tr>
</tbody>
</table>

### Vaccination coverage surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sample size</th>
<th>HepB BD %</th>
<th>HepB3 %</th>
<th>DTP3 %</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2006</td>
<td>National</td>
<td>0-24 months</td>
<td>115</td>
<td>not reported</td>
<td>86%</td>
<td>65%</td>
<td>RMI Community Survey 2006: confirmation method by card only</td>
</tr>
<tr>
<td>2007</td>
<td>Majuro, Ebeye</td>
<td>5-9 years</td>
<td>331</td>
<td>49%</td>
<td>93%</td>
<td>not reported</td>
<td>Bialek Ped Infect Dis 2010</td>
</tr>
<tr>
<td>2007</td>
<td>National</td>
<td>24-35 months</td>
<td>207</td>
<td>not reported</td>
<td>not reported</td>
<td>17% (for age 48-59M); 32% (for age 36-47M)</td>
<td>DHS Survey 2007/ DTP3 by 12 months</td>
</tr>
<tr>
<td>2007</td>
<td>National</td>
<td>12-23 months</td>
<td>249</td>
<td>not reported</td>
<td>not reported</td>
<td>32%</td>
<td>38% by 12 months</td>
</tr>
<tr>
<td>2016</td>
<td>National</td>
<td>24-35 months</td>
<td>1312</td>
<td>87%</td>
<td>76%</td>
<td>72%</td>
<td>MMWR May 25, 2018 / 67(20);579-584</td>
</tr>
</tbody>
</table>

### Current schedule

- **0, 2 months, 4 months, 6 months**
- **HepB3 type**
  - DTP-HepB-IPV

## WHO verification

- **Status of verifying prevalence targets**
  - Verification started: pending
  - Decision: n.a.
  - Decision date: n.a.

### Abbreviations
- DTP3: 3rd dose of Diphteria, Tetanus and Pertussis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours

### Sources
- Total population was from the United Nations World Population Prospects the 2020 revision
- Urban Population was derived from World Bank
- Neonatal deliveries was derived from UNICEF Maternal and Newborn Health Coverage Database (most recent data)
- Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization
**Demographics**

Total population (2020): 115,021
Births (2020): 2,601
Surviving infants (2020): 2,544
Urban population (2020): 21%

**Hepatitis B vaccine**

HepB3 introduced nationwide: 1988
HepB birth dose introduced: 1988
Current schedule: 0, 2 months, 4 months, 6 months
HepB3 type: DTP-HepB-IPV

**WHO verification**

Status of verifying prevalence targets
Verification started: October 2017
Decision: <1% in children
Decision date: March 2018

**Vaccination coverage surveys**

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sample size</th>
<th>HepB BD %</th>
<th>HepB3 %</th>
<th>DTP3 %</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1989</td>
<td>National</td>
<td>2 years</td>
<td>16,391</td>
<td>not reported</td>
<td>84%</td>
<td>not reported</td>
<td>Manoa PH Reports 1992</td>
</tr>
<tr>
<td>1992</td>
<td>Chuuk</td>
<td>2 years</td>
<td>544</td>
<td>not reported</td>
<td>40%</td>
<td>not reported</td>
<td>Mahoney Pac Hth Dialog 1996</td>
</tr>
<tr>
<td>1994</td>
<td>Pohnpei</td>
<td>3-4 years</td>
<td>364</td>
<td>not reported</td>
<td>82%</td>
<td>not reported</td>
<td>Mahoney Pac Hth Dialog 1996</td>
</tr>
<tr>
<td>2000</td>
<td>Chuuk</td>
<td>2-6 years</td>
<td>365</td>
<td>50%</td>
<td>87%</td>
<td>not reported</td>
<td>Bialek ISVHLD P351 2006</td>
</tr>
<tr>
<td>2005</td>
<td>Pohnpei</td>
<td>2-9 years</td>
<td>478</td>
<td>87%</td>
<td>90%</td>
<td>not reported</td>
<td>Bialek Ped Infect Dis 2010</td>
</tr>
<tr>
<td>2005</td>
<td>National</td>
<td>2-9 years</td>
<td>432</td>
<td>75%</td>
<td>91%</td>
<td>not reported</td>
<td>Bialek ISVHLD P351 2006</td>
</tr>
<tr>
<td>2016</td>
<td>Chuuk</td>
<td>24-25 months</td>
<td>1218</td>
<td>54%</td>
<td>78%</td>
<td>72%</td>
<td>MMWR May 25, 2018 / 67(20);579-584</td>
</tr>
</tbody>
</table>

**Hepatitis B serological surveys**

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sampling base</th>
<th>Sample size</th>
<th>HBsAg prevalence (95%CI)</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2005</td>
<td>Chuuk</td>
<td>2-6 years</td>
<td>Hospital based</td>
<td>362</td>
<td>2.5%</td>
<td>Bialek PID 2010</td>
</tr>
<tr>
<td>2005</td>
<td>Pohnpei</td>
<td>2-6 years</td>
<td>Hospital based</td>
<td>478</td>
<td>1.5%</td>
<td>Bialek PID 2010</td>
</tr>
<tr>
<td>2016</td>
<td>National</td>
<td>5-6 years</td>
<td>School based</td>
<td>2106</td>
<td>0.3% (0.1% - 0.5%)</td>
<td>2017 MoH Federated States of Micronesia</td>
</tr>
</tbody>
</table>

**Abbreviations**: DTP3: 3rd dose of Diphtheria, Tetanus and Pertussis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours

**Sources**: Total population, births and surviving infants were from the United Nations World Population Prospects the 2020 revision; Urban Population was derived from World Bank; Unless otherwise noted in the section marked Reference/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization

*HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage.*
**Demographics**

- Total population (2020): 3,278,292
- Births (2020): 73,755
- Surviving infants (2020): 72,552
- Urban population (2020): 67%

**Hepatitis B vaccine**

- HepB3 introduced nationwide: 1991
- HepB birth dose introduced: 1991
- Current schedule: 0, 2 months, 3 months, 4 months
- HepB3 type: DTP-Hib-HepB

**WHO verification**

- Status of verifying prevalence targets: April 2012
- Verification started: April 2012
- Decision: <1% in children
- Decision date: July 2012

**Survey year**

<table>
<thead>
<tr>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sample size</th>
<th>HepB3 %</th>
<th>DTP3 %</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>National</td>
<td>12-23 months</td>
<td>1,255</td>
<td>not reported</td>
<td>89%</td>
<td>Mongolia, Child and Development survey-2000 (MICS-2), 2001</td>
</tr>
<tr>
<td>2004 National</td>
<td>4-6 years</td>
<td>5,894</td>
<td>95%</td>
<td>73%</td>
<td>MoH Mongolia 2011</td>
</tr>
<tr>
<td>2004 National</td>
<td>8 years</td>
<td>1,145</td>
<td>65%</td>
<td>60%</td>
<td>Davaalkham J Epid 2007</td>
</tr>
<tr>
<td>2010 National</td>
<td>12-23 months</td>
<td>944</td>
<td>97%</td>
<td>not reported</td>
<td>Mongolia Child and Development 2005 Survey (MICS-3): DTP3-92% by 12M</td>
</tr>
<tr>
<td>2013 National</td>
<td>12-23 months</td>
<td>1,180</td>
<td>99%</td>
<td>98%</td>
<td>Mongolia Social Indicator Sample Survey: HepB BD 93.1%, HepB3 92.5%, DTP3 92.5% by 12M</td>
</tr>
<tr>
<td>2013 National</td>
<td>24-35 months</td>
<td>1,236</td>
<td>97%</td>
<td>96%</td>
<td>Mongolia Social Indicator Sample Survey :HepB BD 86%, HepB3 84.2%, DTP3 84.2% by 12M</td>
</tr>
</tbody>
</table>

**Vaccination coverage surveys**

- **Survey year**
- **Location**
- **Ages enrolled**
- **Sample size**
- **HepB3 %**
- **DTP3 %**
- **Reference/Notes**

**Hepatitis B serological surveys**

- **Survey year**
- **Location**
- **Ages enrolled**
- **Sampling base**
- **Sample size**
- **HBsAg prevalence (95%CI)**
- **Reference/Notes**

**Abbreviations:**
- DTP3: 3rd dose of Diphteria, Tetanus and Pertussis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours
- Sources: Total population, births and surviving infants were from the United Nations World Population Prospects the 2020 revision; Urban Population was derived from World Bank; Neonatal deliveries was derived from UNICEF Maternal and Newborn Health Coverage Database (most recent data); Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization

*HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage.*
NAURU

Demographics

Total population (2020) 10,834
Births (2019) 335
Surviving infants (2019) 326
Urban population (2020) 100%

Hepatitis B vaccine

HepB3 introduced nationwide 1983
HepB birth dose introduced: Yes, introduction year unknown
Current schedule: 0, 6 weeks, 10 weeks, 14 weeks
HepB3 type: DTP-Hib-HepB

Survey year Location Ages enrolled Sampling base Sample size HepB BD % HepB3 % DTP3 % Reference/Notes

Hepatitis B serological surveys

Survey year Location Ages enrolled Sampling base Sample size HBsAg prevalence (95%CI) Reference/Notes

WHO verification

Status of verifying prevalence targets
Verification started: pending
Decision: n.a.
Decision date: n.a.

Neonatal deliveries

Proportion of deliveries

Women aged 15-49 Women aged 15-19 In health facility
Skilled birth attendant

Hepatitis B vaccination coverage

Vaccination Coverage (%)

Timely HepB BD Any HepB BD HepB3

2020 Districts by coverage categories

% District

<50% <50%-79% 80%-89% 90%-94% >94%

Abbreviations: DTP3: 3rd dose of Diphteria, Tetanus and Pertussis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours
Sources: Total population was from the United Nations World Population Prospects the 2020 revision; Urban Population was derived from World Bank; Neonatal deliveries was derived from UNICEF Maternal and Newborn Health Coverage Database (most recent data); Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization
### Demographics

<table>
<thead>
<tr>
<th>Total population (2020)</th>
<th>285,491</th>
</tr>
</thead>
<tbody>
<tr>
<td>Births (2020)</td>
<td>3,938</td>
</tr>
<tr>
<td>Surviving infants (2020)</td>
<td>3,895</td>
</tr>
<tr>
<td>Urban population (2020)</td>
<td>72%</td>
</tr>
</tbody>
</table>

### Hepatitis B vaccine

<table>
<thead>
<tr>
<th>HepB3 introduced nationwide</th>
<th>1989</th>
</tr>
</thead>
<tbody>
<tr>
<td>HepB birth dose introduced</td>
<td>Yes, introduction year unknown</td>
</tr>
<tr>
<td>Current schedule</td>
<td>0, 2 months, 11 months</td>
</tr>
<tr>
<td>HepB3 type</td>
<td>DTP-Hib-HepB-IPV</td>
</tr>
</tbody>
</table>

### WHO verification

<table>
<thead>
<tr>
<th>Status of verifying prevalence targets</th>
</tr>
</thead>
<tbody>
<tr>
<td>Verification started:</td>
</tr>
<tr>
<td>Decision:</td>
</tr>
<tr>
<td>Decision date:</td>
</tr>
</tbody>
</table>

### Neonatal deliveries

- **Survey year**: 2015, 2016, 2017, 2018, 2019, 2020
- **Location**: Skilled birth attendant
- **Ages enrolled**: Women aged 15-49, Women aged 15-19, In health facility
- **Proportion of deliveries**: 0% to 100%

### Hepatitis B vaccination coverage

#### Survey year
- **Timely HepB BD**: 2015, 2016, 2017, 2018, 2019, 2020
- **HepB3**: 2015, 2016, 2017, 2018, 2019, 2020

#### Timely HepB BD

<table>
<thead>
<tr>
<th>Year</th>
<th>Coverage (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2015</td>
<td>&lt;50%</td>
</tr>
<tr>
<td>2016</td>
<td>&gt;94%</td>
</tr>
<tr>
<td>2017</td>
<td>&gt;94%</td>
</tr>
<tr>
<td>2018</td>
<td>&gt;94%</td>
</tr>
<tr>
<td>2019</td>
<td>&gt;94%</td>
</tr>
<tr>
<td>2020</td>
<td>&gt;94%</td>
</tr>
</tbody>
</table>

#### Any HepB BD

<table>
<thead>
<tr>
<th>Year</th>
<th>Coverage (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2015</td>
<td>&lt;50%</td>
</tr>
<tr>
<td>2016</td>
<td>&lt;50%</td>
</tr>
<tr>
<td>2017</td>
<td>&lt;50%</td>
</tr>
<tr>
<td>2018</td>
<td>&lt;50%</td>
</tr>
<tr>
<td>2019</td>
<td>&lt;50%</td>
</tr>
<tr>
<td>2020</td>
<td>&lt;50%</td>
</tr>
</tbody>
</table>

#### HepB3

<table>
<thead>
<tr>
<th>Year</th>
<th>Coverage (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2015</td>
<td>&lt;50%</td>
</tr>
<tr>
<td>2016</td>
<td>&lt;50%</td>
</tr>
<tr>
<td>2017</td>
<td>&lt;50%</td>
</tr>
<tr>
<td>2018</td>
<td>&lt;50%</td>
</tr>
<tr>
<td>2019</td>
<td>&lt;50%</td>
</tr>
<tr>
<td>2020</td>
<td>&lt;50%</td>
</tr>
</tbody>
</table>

### 2020 Districts by coverage categories

<table>
<thead>
<tr>
<th>District</th>
<th>HepB3</th>
<th>Timely HepB BD</th>
</tr>
</thead>
<tbody>
<tr>
<td>District 1</td>
<td>&gt;94%</td>
<td>&gt;94%</td>
</tr>
<tr>
<td>District 2</td>
<td>&gt;94%</td>
<td>&gt;94%</td>
</tr>
<tr>
<td>District 3</td>
<td>&gt;94%</td>
<td>&gt;94%</td>
</tr>
<tr>
<td>District 4</td>
<td>&gt;94%</td>
<td>&gt;94%</td>
</tr>
<tr>
<td>District 5</td>
<td>&gt;94%</td>
<td>&gt;94%</td>
</tr>
</tbody>
</table>

### Hepatitis B serological surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sampling base</th>
<th>Sample size</th>
<th>HBsAg prevalence (95%CI)</th>
<th>Reference/Notes</th>
</tr>
</thead>
</table>

### Abbreviations

- DTP3: 3rd dose of Diphtheria, Tetanus and Pertussis vaccine
- HepB3: at least 3 doses of hepatitis B vaccine
- HBsAg: hepatitis B surface antigen
- SBA: Skilled Birth Attendant
- Timely HepB BD: birth dose within 24 hours

### Sources

- Total population, births and surviving infants were from the United Nations World Population Prospects the 2020 revision
- Urban Population was derived from World Bank
- Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization
NEW ZEALAND

Demographics
- Total population (2020): 4,822,233
- Births (2020): 59,671
- Surviving infants (2020): 59,459
- Urban population (2020): 87%

Hepatitis B vaccine
- HepB3 introduced nationwide: 1985
- HepB birth dose introduced: If born to HBsAg+ mothers
- Current schedule: 6 weeks, 3 months, 5 months
- HepB3 type: DTP-Hib-HepB-IPV

Vaccination coverage surveys

Survey year | Location | Ages enrolled | Sample size | HepB BD % | HepB3 % | DTP3 % | Reference/Notes
--- | --- | --- | --- | --- | --- | --- | ---
2005 | National | 12 months | 1563 | 72% | 82% | 85% | MoH; 87% HepB3 by 2 years

Hepatitis B serological surveys

Survey year | Location | Ages enrolled | Sampling base | Sample size | HBsAg prevalence (95%CI) | Reference/Notes
--- | --- | --- | --- | --- | --- | ---
2009 | North Islands | 6 years | Health facility | 466 | 0.2% (0.0% - 1.2%) | Weir R. MoH New Zealand 2009

WHO verification
- Status of verifying prevalence targets
  - Verification started: April 2012
  - Decision: <1% in children
  - Decision date: September 2012

Abbreviations: DTP3: 3rd dose of Diphtheria, Tetanus and Pertussis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours
Sources: Total population, births and surviving infants were from the United Nations World Population Prospects the 2020 revision; Urban Population was derived from World Bank; Neonatal deliveries was derived from UNICEF’s Maternal and Newborn Health Coverage Database for delivery in health facility and World Bank’s World Development Indicators for SBA (most recent data); Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization

*HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage.
Demographics

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total population (2020)</td>
<td>1,618</td>
</tr>
<tr>
<td>Births (2019)</td>
<td>23</td>
</tr>
<tr>
<td>Surviving infants (2019)</td>
<td>23</td>
</tr>
<tr>
<td>Urban population (2020)</td>
<td>47%</td>
</tr>
</tbody>
</table>

Hepatitis B vaccine

- HepB3 introduced nationwide: 1986
- HepB birth dose introduced: Yes, introduction year unknown
- Current schedule: 0, 6 weeks, 3 months, 5 months
- HepB3 type: DTP-Hib-HepB-IPV

WHO verification

- Status of verifying prevalence targets:
  - Verification started: November 2015
  - Decision: <1% in children
  - Decision date: February 2017

Neonatal deliveries

- Total population (2020): 1,618
- Births (2019): 23
- Surviving infants (2019): 23
- Urban population (2020): 47%
- HepB3 introduced nationwide: 1986
- HepB birth dose introduced: Yes, introduction year unknown
- Current schedule: 0, 6 weeks, 3 months, 5 months
- HepB3 type: DTP-Hib-HepB-IPV
- Verification started: November 2015
- Decision: <1% in children
- Decision date: February 2017

Vaccination coverage surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sample size</th>
<th>HepB BD %</th>
<th>HepB3 %</th>
<th>DTP3 %</th>
<th>Reference/Notes</th>
</tr>
</thead>
</table>
| 2020 Districts by coverage categories

Hepatitis B serological surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sampling base</th>
<th>Sample size</th>
<th>HBsAg prevalence (95%CI)</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2015</td>
<td>National</td>
<td>5-12 years</td>
<td>School based</td>
<td>183</td>
<td>0.0%</td>
<td>Patel Vaccine 2016</td>
</tr>
</tbody>
</table>

Abbreviations: DTP3: 3rd dose of Diphteria, Tetanus and Pertussis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours

Sources: Total population was from the United Nations World Population Prospects the 2020 revision; Urban Population was derived from World Bank; Neonatal deliveries was derived from UNICEF Maternal and Newborn Health Coverage Database (most recent data); Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization.
Demographics

- Total population (2020): 57,557
- Births (2019): 909
- Surviving infants (2019): 905
- Urban population (2020): 88%

Vaccination coverage surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sample size</th>
<th>HepB BD %</th>
<th>HepB3 %</th>
<th>DTP3 %</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1995</td>
<td>National</td>
<td>3-4 years</td>
<td>200</td>
<td>not reported</td>
<td>94%</td>
<td>not reported</td>
<td>Mahoney Pac Hth Dial 1996</td>
</tr>
<tr>
<td>2005</td>
<td>National</td>
<td>19-35 months</td>
<td>295</td>
<td>100%</td>
<td>94%</td>
<td>not reported</td>
<td></td>
</tr>
<tr>
<td>2016</td>
<td>National</td>
<td>24-35 months</td>
<td>1140</td>
<td>98%</td>
<td>62%</td>
<td>60%</td>
<td>MMWR May 25, 2018 / 67(20);579-584</td>
</tr>
</tbody>
</table>

Hepatitis B vaccine

- HepB3 introduced nationwide: 1988
- HepB birth dose introduced: 1988
- Current schedule: 0, 6 weeks, 4 months, 6 months
- HepB3 type: DTP-HepB-IPV

Hepatitis B serological surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sampling base</th>
<th>Sample size</th>
<th>HBsAg prevalence (95%CI)</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1994</td>
<td>Saipan</td>
<td>3-4 years</td>
<td>Health facility</td>
<td>200</td>
<td>0.5%</td>
<td>Durand Pac Hth Dial 1996</td>
</tr>
<tr>
<td>2014</td>
<td>National</td>
<td>6 years</td>
<td>School based</td>
<td>804</td>
<td>0.0%</td>
<td>CNMI Healthcare Corp. 2015</td>
</tr>
</tbody>
</table>

WHO verification

- Status of verifying prevalence targets
  - Verification started: December 2015
  - Decision: <1% in children
  - Decision date: April 2017

Abbreviations: DTP3: 3rd dose of Diphtheria, Tetanus and Pertussis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours

Sources: Total population was from the United Nations World Population Prospects the 2020 revision; Urban Population was derived from World Bank; Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization.
### Demographics
- Total population (2020): 18,092
- Births (2019): 213
- Surviving infants (2019): 209
- Urban population (2020): 100%

### Hepatitis B vaccine
- HepB3 introduced nationwide: 1989
- HepB birth dose introduced: 1989
- Current schedule: 0, 2 months, 6 months
- HepB3 type: DTP-HepB-IPV
- Verification started: January 2013
- Decision: <1% in children
- Decision date: May 2013

### WHO verification
- Status of verifying prevalence targets

### Vaccination coverage surveys
<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sample size</th>
<th>HepB BD %</th>
<th>HepB3 %</th>
<th>DTP3 %</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2003</td>
<td>National</td>
<td>10-11 years</td>
<td>192</td>
<td>100%</td>
<td>85%</td>
<td>not reported</td>
<td>Bialek ISVHLD P351 2006</td>
</tr>
<tr>
<td>2016</td>
<td>National</td>
<td>24-35 months</td>
<td>259</td>
<td>97%</td>
<td>93%</td>
<td>95%</td>
<td>MMWR May 25, 2018 / 67(20);579-584</td>
</tr>
</tbody>
</table>

### Hepatitis B serological surveys
<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sampling base</th>
<th>Sample size</th>
<th>HBsAg prevalence (95%CI)</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2003</td>
<td>National</td>
<td>10-11 years</td>
<td>Community based</td>
<td>192</td>
<td>0%</td>
<td>Bialek ISVHLD P351 2006</td>
</tr>
<tr>
<td>2008</td>
<td>Main Island</td>
<td>5-7 years</td>
<td>School based</td>
<td>143</td>
<td>0%</td>
<td>MoH Palau 2013</td>
</tr>
</tbody>
</table>

### Abbreviations:
- DTP3: 3rd dose of Diptheria, Tetanus and Pertussis vaccine
- HepB3: at least 3 doses of hepatitis B vaccine
- HBsAg: hepatitis B surface antigen
- SBA: Skilled Birth Attendant
- Timely HepB BD: birth dose within 24 hours

### Sources:
- Total population was from the United Nations World Population Prospects the 2020 revision
- Urban Population was derived from World Bank
- Neonatal deliveries was derived from UNICEF Maternal and Newborn Health Coverage Database (most recent data)
- Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization

---

### Vaccination coverage

#### 2020 Districts by coverage categories

#### Neonatal deliveries
PAPUA NEW GUINEA

Demographics
- Total population (2020): 8,947,027
- Births (2020): 237,474
- Surviving infants (2020): 228,176
- Urban population (2020): 13%

Hepatitis B vaccine
- HepB3 introduced nationwide: 1989
- HepB birth dose introduced: ~2003
- Current schedule: 0, 1 month, 2 months, 3 months
- HepB3 type: DTP-Hib-HepB

Vaccination coverage surveys

Vaccination coverage
- Survey year: 2016-2020
- Ages enrolled: 12-23 months
- Sample size: 2137
- HepB BD %: not reported
- HepB3 %: 65%
- DTP3 %: 67%
- Reference/Notes: National Immunization Coverage Survey

Hepatitis B serological surveys

- Location: Port Moresby, National
- Ages enrolled: 3-5 months, 4-6 years
- Sampling base: Hospital Based, Community based
- Sample size: 31, 2109
- HBsAg prevalence (95%CI): 13%, 2.3%
- Reference/Notes: Nemba ATPaed. 1993, Kitau ASTMH 2015

WHO verification
- Status of verifying prevalence targets
  - Verification started: pending
  - Decision: n.a.
  - Decision date: n.a.

Abbreviations: DTP3: 3rd dose of Diphtheria, Tetanus and Pertussis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours

Sources: Total population, births and surviving infants were from the United Nations World Population Prospects the 2020 revision; Urban Population was derived from World Bank; Neonatal deliveries was derived from UNICEF Maternal and Newborn Health Coverage Database (most recent data); Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization

Footnote: *HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage.
Demographics

- Total population (2020): 109,581,085
- Births (2020): 2,182,501
- Surviving infants (2020): 2,142,391
- Urban population (2020): 47%

Hepatitis B vaccine

- HepB3 introduced nationwide: 1991
- HepB birth dose introduced: 2007
- Current schedule: 0, 6 weeks, 10 weeks, 14 weeks
- HepB3 type: DTP-Hib-HepB

Neonatal deliveries

- Proportion of deliveries by Skilled birth attendant:
  - Women aged 15–49
  - Women aged 15–19
  - In health facility

Hepatitis B vaccination coverage

- Survey year: 2016-2020
- Vaccination coverage (%):
  - Timely HepB BD
  - Any HepB BD
  - HepB3

2020 Districts by coverage categories*

- District coverage categories:
  - <50%
  - <50%-79%
  - 80%-89%
  - 90%-94%
  - >94%

WHO verification

- Status of verifying prevalence targets:
  - Verification started: pending
  - Decision: n.a.
  - Decision date: n.a.

Vaccination coverage surveys

- Survey year: 1998-2013
- Location: National
- Ages enrolled: 12-23 months
- Sample size: 1474
- HepB BD %: not reported
- HepB3 %: not reported
- DTP3 %: 81%
- Reference/Notes: DHS Survey: DTP3 79% by 12 months

Hepatitis B serological surveys

- Survey year: 2018
- Location: National
- Ages enrolled: 5-7 years
- Sampling base: Household survey
- Sample size: 2,178
- HBsAg prevalence (95%CI): 0.8%
- Reference/Notes: Minta PubMed 2021

Abbreviations: DTP3: 3rd dose of Diphteria, Tetanus and Pertusis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours

Sources: Total population, births and surviving infants were from the United Nations World Population Prospects the 2020 revision; Urban Population was derived from World Bank; Neonatal deliveries was derived from UNICEF Maternal and Newborn Health Coverage Database (most recent data); Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization

*HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage.
REPUBLIC OF KOREA

Demographics

<table>
<thead>
<tr>
<th>Category</th>
<th>2020 Data</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total population</td>
<td>51,269,183</td>
</tr>
<tr>
<td>Births</td>
<td>358,793</td>
</tr>
<tr>
<td>Surviving infants</td>
<td>358,115</td>
</tr>
<tr>
<td>Urban population</td>
<td>82%</td>
</tr>
</tbody>
</table>

Hepatitis B vaccine

- HepB3 introduced nationwide: 1983
- HepB birth dose introduced: 1983
- Current schedule: 0, 1 month, 6 months
- HepB3 type: Monovalent

Vaccination coverage surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sample size</th>
<th>HepB BD %</th>
<th>HepB3 %</th>
<th>DTP3 %</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2008</td>
<td>National</td>
<td>0-6 years</td>
<td>1026</td>
<td>100%</td>
<td>93%</td>
<td>95%</td>
<td>CDC Korea; provided during 2012 TAG</td>
</tr>
<tr>
<td>2009</td>
<td>National</td>
<td>19-35 months</td>
<td>not reported</td>
<td>not reported</td>
<td>99%</td>
<td>99%</td>
<td>2009 Korea National Immunization Survey (Confirmation method NA)</td>
</tr>
<tr>
<td>2011</td>
<td>National</td>
<td>0-3 years</td>
<td>7040</td>
<td>99%</td>
<td>98%</td>
<td>93%</td>
<td>CDC Korea; provided during 2012 TAG</td>
</tr>
</tbody>
</table>

Hepatitis B serological surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sampling base</th>
<th>Sample size</th>
<th>HBsAg prevalence (95%CI)</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2005</td>
<td>National</td>
<td>10-14 years</td>
<td>Community based</td>
<td>594</td>
<td>0.2% (0.0% - 0.6%)</td>
<td>CDC Korea 2008</td>
</tr>
<tr>
<td>2007</td>
<td>National</td>
<td>4-6 years</td>
<td>Hospital based</td>
<td>2920</td>
<td>0.2% (0.0% - 0.4%)</td>
<td>CDC Korea 2008</td>
</tr>
<tr>
<td>2014</td>
<td>National</td>
<td>10-18 years</td>
<td>Community based</td>
<td>510</td>
<td>0.1%</td>
<td>KNHANES 2014</td>
</tr>
</tbody>
</table>

WHO verification

<table>
<thead>
<tr>
<th>Status of verifying prevalence targets</th>
</tr>
</thead>
<tbody>
<tr>
<td>Verification started: January 2008</td>
</tr>
<tr>
<td>Decision: &lt;1% in children</td>
</tr>
<tr>
<td>Decision date: June 2008</td>
</tr>
</tbody>
</table>

Neonatal deliveries

- Births (2020): 358,793
- Surviving infants (2020): 358,115
- Urban population (2020): 82%

Survey year | Location | Ages enrolled | Sample size | HepB BD % | HepB3 % | DTP3 % | Reference/Notes |
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>2008</td>
<td>National</td>
<td>0-6 years</td>
<td>1026</td>
<td>100%</td>
<td>93%</td>
<td>95%</td>
<td>CDC Korea; provided during 2012 TAG</td>
</tr>
<tr>
<td>2009</td>
<td>National</td>
<td>19-35 months</td>
<td>not reported</td>
<td>not reported</td>
<td>99%</td>
<td>99%</td>
<td>2009 Korea National Immunization Survey (Confirmation method NA)</td>
</tr>
<tr>
<td>2011</td>
<td>National</td>
<td>0-3 years</td>
<td>7040</td>
<td>99%</td>
<td>98%</td>
<td>93%</td>
<td>CDC Korea; provided during 2012 TAG</td>
</tr>
</tbody>
</table>

Abbreviations: DTP3: 3rd dose of Diphtheria, Tetanus and Pertussis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours

Sources: Total population, births and surviving infants were from the United Nations World Population Prospects the 2020 revision; Urban Population was derived from World Bank; Neonatal deliveries was derived from UNICEF Maternal and Newborn Health Coverage Database (most recent data); Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization
SAMOA

Demographics

- Total population (2020): 198,410
- Births (2020): 4,761
- Surviving infants (2020): 4,701
- Urban population (2020): 18%

Hepatitis B vaccine

- HepB3 introduced nationwide: 1990
- HepB birth dose introduced: Yes, introduction year unknown
- Current schedule: 0, 6 weeks, 10 weeks, 14 weeks
- HepB3 type: DTP-Hib-HepB

WHO verification

- Status of verifying prevalence targets:
  - Verification started: pending
  - Decision: n.a.
  - Decision date: n.a.

Neonatal deliveries

- Total population (2020): 198,410
- Births (2020): 4,761
- Surviving infants (2020): 4,701
- Urban population (2020): 18%

Hepatitis B vaccination coverage

- HepB3 introduced nationwide: 1990
- HepB birth dose introduced: Yes, introduction year unknown
- Current schedule: 0, 6 weeks, 10 weeks, 14 weeks
- HepB3 type: DTP-Hib-HepB

WHO verification

- Status of verifying prevalence targets:
  - Verification started: pending
  - Decision: n.a.
  - Decision date: n.a.

Vaccination coverage surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sample size</th>
<th>HepB BD %</th>
<th>HepB3 %</th>
<th>DTP3 %</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2009</td>
<td>National</td>
<td>12-24 months</td>
<td>321</td>
<td>70%</td>
<td>not reported</td>
<td>not reported</td>
<td>DHS Survey</td>
</tr>
<tr>
<td>2009</td>
<td>National</td>
<td>18-29 months</td>
<td>321</td>
<td>not reported</td>
<td>not reported</td>
<td>38%</td>
<td>DHS Survey; 37% DTP3 by 12 months</td>
</tr>
<tr>
<td>2014</td>
<td>National</td>
<td>48-59 months</td>
<td>559</td>
<td>75%</td>
<td>45%</td>
<td>45%</td>
<td>DHS Survey; by 12 months</td>
</tr>
<tr>
<td>2014</td>
<td>National</td>
<td>36-47 months</td>
<td>605</td>
<td>81%</td>
<td>50%</td>
<td>50%</td>
<td>DHS Survey; by 12 months</td>
</tr>
<tr>
<td>2014</td>
<td>National</td>
<td>24-35 months</td>
<td>680</td>
<td>82%</td>
<td>54%</td>
<td>54%</td>
<td>DHS Survey; by 12 months</td>
</tr>
<tr>
<td>2015</td>
<td>National</td>
<td>12-23 months</td>
<td>674</td>
<td>84%</td>
<td>64%</td>
<td>64%</td>
<td>DHS Survey; by 12 months</td>
</tr>
<tr>
<td>2015</td>
<td>National</td>
<td>18-29 months</td>
<td>666</td>
<td>83%</td>
<td>64%</td>
<td>64%</td>
<td>DHS Survey; by 18 months 83% HepB, 63% HepB3 and 63% DTP3</td>
</tr>
</tbody>
</table>

Hepatitis B serological surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sampling base</th>
<th>Sample size</th>
<th>HBsAg prevalence (95%CI)</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2014</td>
<td>National</td>
<td>5-6 years</td>
<td>School based</td>
<td>1776</td>
<td>0.11%</td>
<td>MoH Samoa 2015</td>
</tr>
</tbody>
</table>

Abbreviations: DTP3: 3rd dose of Diphtheria, Tetanus and Pertussis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours

Sources: Total population, births and surviving infants were from the United Nations World Population Prospects the 2020 revision; Urban Population was derived from World Bank; Neonatal deliveries was derived from UNICEF Maternal and Newborn Health Coverage Database (most recent data); Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization

*HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage.
SINGAPORE

Demographics
- Total population (2020): 5,850,343
- Births (2020): 49,976
- Surviving infants (2020): 49,901
- Urban population (2020): 100%

Hepatitis B vaccine
- HepB3 introduced nationwide: 1985
- HepB birth dose introduced: 1987
- Current schedule: 0, 1 month, 5-6 months
- HepB3 type: Monovalent

WHO verification
- Status of verifying prevalence targets
  - Verification started: April 2015
  - Decision: <1% in children
  - Decision date: October 2015

Neonatal deliveries
- Urban population: 100%
- HepB3 introduced nationwide: 1985
- HepB birth dose introduced: 1987
- Current schedule: 0, 1 month, 5-6 months
- HepB3 type: Monovalent

Vaccination coverage surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sample size</th>
<th>HepB BD %</th>
<th>HepB3 %</th>
<th>DTP3 %</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2007</td>
<td>National</td>
<td>2 years</td>
<td>31,778</td>
<td>not reported</td>
<td>94%-96%</td>
<td>97%</td>
<td></td>
</tr>
</tbody>
</table>

Hepatitis B serological surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sampling base</th>
<th>Sample size</th>
<th>HBsAg prevalence (95%CI)</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1998-1999</td>
<td>National</td>
<td>0-4 years</td>
<td>Not reported</td>
<td>229</td>
<td>0%</td>
<td>Epi News Bull SNG 2000</td>
</tr>
<tr>
<td>2008-2010</td>
<td>Two hospitals</td>
<td>1-17 years</td>
<td>Hospital based</td>
<td>1200</td>
<td>0.3% (0.1%-0.9%)</td>
<td>Ang J Med Virol 2013</td>
</tr>
</tbody>
</table>

Abbreviations: DTP3: 3rd dose of Diphtheria, Tetanus and Pertussis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours

Sources: Total population, births and surviving infants were from the United Nations World Population Prospects the 2020 revision; Total population was from the United Nations World Population Prospects the 2020 revision; Urban Population was derived from World Bank; Neonatal deliveries was derived from UNICEF’s Material and Newborn Health Coverage Database for delivery in health facility and World Bank’s World Development Indicators for SBA (most recent data); Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization.
SOLOMON ISLANDS

Demographics
- Total population (2020): 686,878
- Births (2020): 21,589
- Surviving infants (2020): 21,277
- Urban population (2020): 23%

Hepatitis B vaccine
- HepB3 introduced nationwide: 1990
- HepB birth dose introduced: ~2005
- Current schedule: 0, 6 weeks, 10 weeks, 14 weeks
- HepB3 type: DTP-Hib-HepB

WHO verification
- Status of verifying prevalence targets: pending
- Verification started: n.a.
- Decision: n.a.
- Decision date: n.a.

Neonatal deliveries

Hepatitis B vaccination coverage

2020 Districts by coverage categories*

Survey year Location Ages enrolled Sample size HepB BD % HepB3 % DTP3 % Reference/Notes
2006-2007 National 48-59 months 477 not reported not reported 72% DHS Survey (DTP3 by 12 months)
2006-2007 National 36-47 months 515 not reported not reported 81% DHS Survey (DTP3 by 12 months)
2006-2007 National 24-35 months 533 not reported not reported 80% DHS Survey (DTP3 by 12 months)
2006-2007 National 12-23 months 535 not reported not reported 88% DHS Survey (87% DTP3 by 12 months)

Hepatitis B serological surveys

Survey year Location Ages enrolled Sampling base Sample size HBsAg prevalence (95%CI) Reference/Notes
1999 Guadalcanal Islands 0-9 years Hospital based 115 13% Furusyo Am J Trop 1999
2016 National 6-7 years School based 1,169 3.1% (2.0% - 4.9%) Breakwell Vaccine 2020

Abbreviations: DTP3: 3rd dose of Diphtheria, Tetanus and Pertussis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours
Sources: Total population, births and surviving infants were from the United Nations World Population Prospects the 2020 revision; Urban Population was derived from World Bank; Neonatal deliveries was derived from UNICEF Maternal and Newborn Health Coverage Database (most recent data); Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization

*HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage.
TOKELAU

Demographics

<table>
<thead>
<tr>
<th>Total population (2020)</th>
<th>1,350</th>
</tr>
</thead>
<tbody>
<tr>
<td>Births (2020)</td>
<td>35</td>
</tr>
<tr>
<td>Surviving infants (2020)</td>
<td>28</td>
</tr>
<tr>
<td>Urban population (2020)</td>
<td>0%</td>
</tr>
</tbody>
</table>

Hepatitis B vaccine

- HepB3 introduced nationwide: 1990
- HepB birth dose introduced: 1990
- Current schedule: 0, 6 weeks, 10 weeks, 14 weeks
- HepB3 type: DTP-Hib-HepB

Survey year | Location | Ages enrolled | Sample size | HepB BD % | HepB3 % | DTP3 % | Reference/Notes |
-------------|----------|---------------|-------------|-----------|---------|--------|-----------------|
2014 National | 6-12 years | School based | 171         | 0.0%      |         |        | Patel Vaccine 2016 |

WHO verification

- Status of verifying prevalence targets
  - Verification started: May 2015
  - Decision: <1% in children
  - Decision date: June 2016

Neonatal deliveries

Survey year | Location | Ages enrolled | Sample size | HepB BD % | HepB3 % | DTP3 % | Reference/Notes |
-------------|----------|---------------|-------------|-----------|---------|--------|-----------------|
2014 National | 6-12 years | School based | 171         | 0.0%      |         |        | Patel Vaccine 2016 |

Vaccination coverage surveys

Survey year | Location | Ages enrolled | Sample size | HepB BD % | HepB3 % | DTP3 % | Reference/Notes |
-------------|----------|---------------|-------------|-----------|---------|--------|-----------------|
2014 National | 6-12 years | School based | 171         | 0.0%      |         |        | Patel Vaccine 2016 |

Hepatitis B serological surveys

Survey year | Location | Ages enrolled | Sampling base | Sample size | HBsAg prevalence (95%CI) | Reference/Notes |
-------------|----------|---------------|---------------|-------------|-------------------------|-----------------|
2014 National | 6-12 years | School based | 171         | 0.0%      |                         | Patel Vaccine 2016 |

Abbreviations: DTP3: 3rd dose of Diphteria, Tetanus and Pertussis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours

Sources: Total population was from the United Nations World Population Prospects the 2020 revision; Urban Population was derived from World Bank; Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization

*HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage.
Demographics

- Total population (2020): 105,697
- Births (2020): 2,502
- Surviving infants (2020): 2,473
- Urban population (2020): 24%

Hepatitis B vaccine

- HepB3 introduced nationwide: 1988
- HepB birth dose introduced: 1988
- Current schedule: 0, 6 weeks, 10 weeks, 14 weeks
- HepB3 type: DTP-Hib-HepB

WHO verification

- Status of verifying prevalence targets
- Verification started: May 2011
- Decision: <2% in children
- Decision date: January 2012

Neonatal deliveries

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sample size</th>
<th>HepB BD %</th>
<th>HepB3 %</th>
<th>DTP3 %</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2003</td>
<td>National</td>
<td>12-23 months</td>
<td>114</td>
<td>not reported</td>
<td>94%</td>
<td>96%</td>
<td>Evaluation of Immunization Program of the Kingdom of Tonga</td>
</tr>
<tr>
<td>2005</td>
<td>Tongatapu hospital</td>
<td>6-59 months</td>
<td>445</td>
<td>92%</td>
<td>98%</td>
<td>98%</td>
<td>Danielsson Vaccine 2009</td>
</tr>
<tr>
<td>2012</td>
<td>National</td>
<td>48-59 months</td>
<td>302</td>
<td>not reported</td>
<td>61%</td>
<td>61%</td>
<td>DHS Survey (HepB3 and DTP3 by 12 months)</td>
</tr>
<tr>
<td>2012</td>
<td>National</td>
<td>36-47 months</td>
<td>334</td>
<td>not reported</td>
<td>59%</td>
<td>59%</td>
<td>DHS Survey (HepB3 and DTP3 by 12 months)</td>
</tr>
<tr>
<td>2012</td>
<td>National</td>
<td>24-35 months</td>
<td>383</td>
<td>not reported</td>
<td>60%</td>
<td>60%</td>
<td>DHS Survey (HepB3 and DTP3 by 12 months)</td>
</tr>
<tr>
<td>2012</td>
<td>National</td>
<td>12-23 months</td>
<td>307</td>
<td>not reported</td>
<td>66%</td>
<td>66%</td>
<td>DHS Survey (65% HepB3 and 65% DTP3 by 12 months)</td>
</tr>
</tbody>
</table>

Hepatitis B vaccination coverage

- Timely HepB BD
- Any HepB BD
- HepB3

2020 Districts by coverage categories

<table>
<thead>
<tr>
<th>District</th>
<th>&lt;50%</th>
<th>&lt;50%-79%</th>
<th>80%-89%</th>
<th>90%-94%</th>
<th>&gt;94%</th>
</tr>
</thead>
<tbody>
<tr>
<td>HepB3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Timely HepB BD</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Vaccination coverage surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sample size</th>
<th>HepB BD %</th>
<th>HepB3 %</th>
<th>DTP3 %</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1998</td>
<td>Large Towns</td>
<td>12-24 months</td>
<td>211</td>
<td>3.8%</td>
<td></td>
<td></td>
<td>Wilson Vaccine 2000</td>
</tr>
<tr>
<td>2005</td>
<td>Main Island</td>
<td>6-59 months</td>
<td>375</td>
<td>0.8% (0.2% - 2.5%)</td>
<td></td>
<td></td>
<td>Danielsson Vaccine 2009</td>
</tr>
</tbody>
</table>

Hepatitis B serological surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sampling base</th>
<th>Sample size</th>
<th>HBsAg prevalence (95%CI)</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1998</td>
<td>Large Towns</td>
<td>12-24 months</td>
<td>Hospital based</td>
<td>211</td>
<td>3.8%</td>
<td>Wilson Vaccine 2000</td>
</tr>
<tr>
<td>2005</td>
<td>Main Island</td>
<td>6-59 months</td>
<td>Hospital based</td>
<td>375</td>
<td>0.8% (0.2% - 2.5%)</td>
<td>Danielsson Vaccine 2009</td>
</tr>
</tbody>
</table>

Abbreviations: DTP3: 3rd dose of Diphtheria, Tetanus and Pertussis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepBBD: birth dose within 24 hours

Sources: Total population, births and surviving infants were from the United Nations World Population Prospects the 2020 revision; Urban Population was derived from World Bank; Neonatal deliveries was derived from UNICEF Maternal and Newborn Health Coverage Database (most recent data); Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization

*HepB3 vaccine coverage when available, otherwise graph represents DPT3 coverage.
TUVALU

Demographics

- Total population (2020): 11,792
- Births (2019): 307
- Surviving infants (2019): 307
- Urban population (2020): 62%

Hepatitis B vaccine

- HepB3 introduced nationwide: Yes, introduction year unknown
- HepB birth dose introduced: Yes, introduction year unknown
- Current schedule: 0, 6 weeks, 10 weeks, 14 weeks
- HepB3 type: DTP-Hib-HepB

Neonatal deliveries

Survey year | Location | Ages enrolled | Sample size | HepB BD % | HepB3 % | DTP3 % | Reference/Notes
---|---|---|---|---|---|---|---
2007 | National | 48-59 months | 75 | not reported | not reported | 59% | DHS Survey (DTP3 by 18 months)
2007 | National | 36-47 months | 84 | not reported | not reported | 57% | DHS Survey (DTP3 by 18 months)
2007 | National | 24-35 months | 89 | not reported | not reported | 60% | DHS Survey (DTP3 by 18 months)
2007 | National | 18-29 months | 80 | not reported | not reported | 62% | DHS Survey (60% DTP3 by 18 months)

Hepatitis B vaccination coverage

Survey year | Location | Ages enrolled | Sample size | HBsAg prevalence (95%CI) | Reference/Notes
---|---|---|---|---|---
1976 | Fanafuti | 10-19 years | Community based | 181 | 11% | Gust JID 1979

WHO verification

- Status of verifying prevalence targets
  - Verification started: pending
  - Decision: n.a.
  - Decision date: n.a.

Vaccination coverage surveys

Abbreviations: DTP3: 3rd dose of Diphtheria, Tetanus and Pertussis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours

Sources: Total population was from the United Nations World Population Prospects the 2020 revision; Urban Population was derived from World Bank; Neonatal deliveries was derived from UNICEF Maternal and Newborn Health Coverage Database (most recent data); Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization

*HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage.
VANUATU

Demographics

- Total population (2020): 307,150
- Births (2020): 8,838
- Surviving infants (2020): 8,654
- Urban population (2020): 24%

Hepatitis B vaccine

- HepB3 introduced nationwide: 1989-1990
- Current schedule: 0, 6 weeks, 10 weeks, 14 weeks
- HepB3 type: DTP-Hib-HepB

WHO verification

- Status of verifying prevalence targets
  - Verification started: pending
  - Decision: n.a.
  - Decision date: n.a.

Neonatal deliveries

Survey year | Location | Ages enrolled | Sample size | HepB BD % | HepB3 % | DTP3 % | Reference/Notes
--- | --- | --- | --- | --- | --- | --- | ---
2007 | National | 12-23 months | 359 | not reported | 59% | 63% | MICS; by 12 months 55% HepB3, 58% DTP3
2013 | National | 12-23 months | 303 | not reported | 55% | 55% | DHS Survey; by 12 months 49% HepB3, 49% DTP3

Hepatitis B vaccination coverage

- Timely HepB BD
- Any HepB BD
- HepB3

2020 Districts by coverage categories*

- <50%
- 50%-79%
- 80%-89%
- 90%-94%
- >94%

---

Vaccination coverage surveys

Survey year | Location | Ages enrolled | Sample size | HepB BD % | HepB3 % | DTP3 % | Reference/Notes
--- | --- | --- | --- | --- | --- | --- | ---
2007 | National | 12-23 months | 359 | not reported | 59% | 63% | MICS; by 12 months 55% HepB3, 58% DTP3
2013 | National | 12-23 months | 303 | not reported | 55% | 55% | DHS Survey; by 12 months 49% HepB3, 49% DTP3

Hepatitis B serological surveys

Survey year | Location | Ages enrolled | Sampling base | Sample size | HBsAg prevalence (95%CI) | Reference/Notes
--- | --- | --- | --- | --- | --- | ---
1988 | Emao or Nguna | 12-18 months | Community based | 112 | 17% | Maher Med J Aust 1991
1998 | Large Towns | 12-24 months | Hospital based | 132 | 3.0% | Wilson Vaccine 2000

Abbreviations: DTP3: 3rd dose of Diphtheria, Tetanus and Pertussis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours
Sources: Total population, births and surviving infants were from the United Nations World Population Prospects the 2020 revision; Urban Population was derived from World Bank; Neonatal deliveries was derived from UNICEF Maternal and Newborn Health Coverage Database (most recent data); Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization

*HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage.
VIET NAM

Demographics
Total population (2020) 97,338,583
Births (2020) 1,566,556
Surviving infants (2020) 1,541,383
Urban population (2020) 38%

Hepatitis B vaccine
HepB3 introduced nationwide 1997
HepB birth dose introduced 2005
Current schedule 0, 2 months, 3 months, 4 months
HepB3 type DTP-Hib-HepB

WHO verification
Status of verifying prevalence targets
Verification started: pending
Decision: n.a.
Decision date: n.a.

Neonatal deliveries

<table>
<thead>
<tr>
<th>Year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sample size</th>
<th>HepB BD %</th>
<th>HepB3 %</th>
<th>DTP3 %</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2002</td>
<td>National</td>
<td>12-24 months</td>
<td>457</td>
<td>not reported</td>
<td>not reported</td>
<td>72%</td>
<td>DHS Survey</td>
</tr>
<tr>
<td>2006</td>
<td>National</td>
<td>12-23 months</td>
<td>555</td>
<td>not reported</td>
<td>34%</td>
<td>79%</td>
<td>MICS; 32% HepB3 and 76% DTP3 by 12 months</td>
</tr>
<tr>
<td>2002-2003</td>
<td>National</td>
<td>12-23 months</td>
<td>457</td>
<td>not reported</td>
<td>not reported</td>
<td>72%</td>
<td>DHS Survey</td>
</tr>
<tr>
<td>2010-2011</td>
<td>National</td>
<td>12-23 months</td>
<td>759</td>
<td>not reported</td>
<td>56%</td>
<td>74%</td>
<td>MICS; 53% HepB3 and 73% DTP3 by 12 months</td>
</tr>
<tr>
<td>2014</td>
<td>National</td>
<td>24-35 months</td>
<td>641</td>
<td>71%</td>
<td>92%</td>
<td>93%</td>
<td>MICS; 71% HepB BD, 92% HepB3 and 93% DTP3 by 12 months</td>
</tr>
<tr>
<td>2014</td>
<td>National</td>
<td>12-23 months</td>
<td>790</td>
<td>78%</td>
<td>87%</td>
<td>89%</td>
<td>MICS; 78% HepB BD, 87% HepB3 and 89% DTP3 by 12 months</td>
</tr>
<tr>
<td>2015</td>
<td>National</td>
<td>12-23 months</td>
<td>2417</td>
<td>56%</td>
<td>98%</td>
<td>85%</td>
<td>WHO-UNICEF Joint Reporting Form (data for 2017)</td>
</tr>
</tbody>
</table>

Hepatitis B vaccination coverage

- Timely HepB BD
- Any HepB BD
- HepB3

2020 Districts by coverage categories*

<table>
<thead>
<tr>
<th>Districts by coverage categories</th>
<th>Timely HepB BD</th>
<th>Any HepB BD</th>
<th>HepB3</th>
</tr>
</thead>
<tbody>
<tr>
<td>&gt;94%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>90%-94%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>80%-89%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>70%-79%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;50%</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Hepatitis B serological surveys

<table>
<thead>
<tr>
<th>Survey year</th>
<th>Location</th>
<th>Ages enrolled</th>
<th>Sampling base</th>
<th>Sample size</th>
<th>HBsAg prevalence (95%CI)</th>
<th>Reference/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1998</td>
<td>Thanh Hoa</td>
<td>9-18 months</td>
<td>Community based</td>
<td>536</td>
<td>12.5% (1.25%-2.15%)</td>
<td>Hipgrave AJTMH 2003</td>
</tr>
<tr>
<td>2011</td>
<td>National</td>
<td>3-4 years</td>
<td>Community based</td>
<td>3426</td>
<td>1.6% (1.25%-2.15%)</td>
<td>Nguyen Vaccine 2014</td>
</tr>
<tr>
<td>2011</td>
<td>National</td>
<td>5-7 years</td>
<td>Community based</td>
<td>1738</td>
<td>2.2% (1.47%-3.14%)</td>
<td>Nguyen Vaccine 2014</td>
</tr>
<tr>
<td>2011</td>
<td>National</td>
<td>8-11 years</td>
<td>Community based</td>
<td>1740</td>
<td>3.6% (2.80%-4.71%)</td>
<td>Nguyen Vaccine 2014</td>
</tr>
</tbody>
</table>

Abbreviations: DTP3: 3rd dose of Diphtheria, Tetanus and Pertussis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours
Sources: Total population, births and surviving infants were from the United Nations World Population Prospects the 2020 revision; Urban Population was derived from World Bank; Neonatal deliveries was derived from UNICEF Maternal and Newborn Health Coverage Database (most recent data); Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization

*HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage.
**Demographics**

- Total population (2020): 11,246
- Births (2019): 147
- Surviving infants (2019): 146
- Urban population (2020): 0%

**Hepatitis B vaccine**

- HepB3 introduced nationwide: Yes, introduction year unknown
- HepB birth dose introduced: Yes, introduction year unknown
- Current schedule: 0, 2 months, 11 months
- HepB3 type: DTP-Hib-HepB-IPV

**WHO verification**

- Verification started: pending
- Decision: n.a.
- Decision date: n.a.

**Neonatal deliveries**

- 2011 National: 7-12 years, 442 not reported, 94% not reported (Data from national serosurvey)

**Hepatitis B vaccination coverage**

- 2011 National: 9-11 years, School-based, 428, 0.93% (Preliminary data)

**2020 Districts by coverage categories**

- 2011 National: Districts by coverage categories

**Hepatitis B serological surveys**

- 2012 National: 9-11 years, School-based, 428, 0.93% (Preliminary data)

**Vaccination coverage surveys**

- 2011 National: 7-12 years, 442, not reported, 94%, not reported (Data from national serosurvey)

**Sources**

- Total population was from the United Nations World Population Prospects the 2017 revision
- Urban Population was derived from World Bank
- Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization